Rare Disease

Latest News

FDA Sets PDUFA Date, Accepts BLA Submission for Pz-cel in Epidermolysis Bullosa
FDA Sets PDUFA Date, Accepts BLA Submission for Pz-cel in Epidermolysis Bullosa

November 12th 2024

Abeona's pz-cel has been granted a April 29, 2025, PDUFA date.

Benvitimod is Safe for Palmoplantar Pustulosis, New Study Finds
Benvitimod is Safe for Palmoplantar Pustulosis, New Study Finds

October 29th 2024

Breakthrough CRISPR/Cas9 Technique Achieves 95% Exon Deletion for Epidermolysis Bullosa Treatment
Breakthrough CRISPR/Cas9 Technique Achieves 95% Exon Deletion for Epidermolysis Bullosa Treatment

August 6th 2024

Pediatric Emergency Department Visits with Dystrophic Epidermolysis Bullosa More Frequent in Summer; Hospitalization Rates Exceed 50%
Pediatric Emergency Department Visits with Dystrophic Epidermolysis Bullosa More Frequent in Summer; Hospitalization Rates Exceed 50%

July 29th 2024

Rituximab May Provide Alternative Treatment Option for Epidermolysis Bullosa Acquisita
Rituximab May Provide Alternative Treatment Option for Epidermolysis Bullosa Acquisita

July 25th 2024

Latest CME Events & Activities

Cancer Summaries and Commentaries™: Clinical Updates in Melanoma from Philadelphia

View More

Dermalorian™ Webinar Series on Moderate to Severe Atopic Dermatitis

November 21, 2024 - December 5, 2024

View More

21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies®

February 8, 2025

View More

Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis

View More

Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making

View More

Clinical Consultations™: Optimizing Treatment Outcomes for Patients with Generalized Pustular Psoriasis

View More

Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color

View More

Clinical Consultations™: Guiding Patients with Genital Psoriasis Toward Relief Through a Multidisciplinary Approach

View More

Patient, Provider & Caregiver Connection™: Understanding the Patient Journey to Provide Personalized Care for Generalized Pustular Psoriasis

View More

Cases and Conversations™: Applying Practice Techniques to Optimize Diagnosis and Treatment Strategies in Generalized Pustular Psoriasis

View More

Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice

View More

‘REEL’ Time Patient Counseling™: Fostering Effective Conversations in Practice to Create a Visible Impact for Patients Living with Genital Psoriasis

View More

More News

© 2024 MJH Life Sciences

All rights reserved.